Company Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products.
Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.
It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology.
The company was incorporated in 2016 and is headquartered in Orlando, Florida.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Gareth Sheridan |
Contact Details
Address: 121 S. Orange Ave., Suite 1500 Orlando, Florida 32801 United States | |
| Phone | 407 377-6695 |
| Website | nutriband.com |
Stock Details
| Ticker Symbol | NTRB |
| Exchange | NASDAQ |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| CIK Code | 0001676047 |
| CUSIP Number | 67092M208 |
| ISIN Number | US67092M2089 |
| Employer ID | 81-1118176 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Serguei Melnik | Founder, President, Company Secretary and Executive Chairman of the Board |
| Gareth Sheridan | Founder, Chief Executive Officer and Director |
| Gerald Goodman | Chief Financial Officer and Chief Accounting Officer |
| Dr. Alan Smith Ph.D. | Chief Operating Officer and President of 4P Therapeutics |
| Patrick Ryan | Chief Technical Officer |
| Dr. Jeffrey Patrick Pharm.D. | Chief Scientific Officer |
| Tyler Overk | President of Active Intelligence |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 25, 2024 | 8-K | Current Report |
| Jan 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Jan 11, 2024 | 8-K | Current Report |
| Dec 29, 2023 | 8-K | Current Report |
| Dec 15, 2023 | DEF 14A | Other definitive proxy statements |
| Dec 13, 2023 | 10-Q | Quarterly Report |